A Preclinical Field–Immune Study

Immune activity involves many interacting pathways. A change in one laboratory measure under a particular field exposure does not mean all inflammatory responses can be adjusted safely in patients.

A specific experiment

Díaz-Del Cerro and De la Fuente examined NEURALTER low-frequency PEMF in old female CD1 mice treated for 15 minutes per day for four weeks, along with directly exposed mouse leukocytes. They measured behavior and immune, inflammatory and redox endpoints. These findings are limited to that experimental setup; they do not establish clinical immune repair or safe dosing for people.

Separating pathways from outcomes

Claims about IL-6, TNF-alpha, NF-κB, macrophage polarization or lymphocyte behavior would each require a clearly identified study, exposure, species and endpoint. The linked abstract is not sufficient to infer one universal master switch. Nor was a specific osteoarthritis systematic review identified and checked for this article, so no conclusion from one is presented.

A responsive exposure system would require a validated measurement, a prespecified adjustment rule and testing of both benefit and adverse effects at the intended dose in the intended patients. A “drug-free” label is not evidence of safety or a reason to substitute it for established treatment.

Measuring immune responses to defined field exposure Specify frequency, intensity, and exposure

Measure defined immune pathways

Assess disease-relevant outcomes separately

What the linked references do not establish: The immune-response findings are from old mice; they do not establish clinical immune modulation or safe dosing in people.